New chemo cocktail aims to make stem cell transplants safer for seniors

NCT ID NCT03352765

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a combination of three drugs (rituximab, bendamustine, and melphalan) followed by a stem cell transplant using the patient's own cells. The goal is to see if this approach is safe and has fewer side effects than standard treatments for older adults with multiple myeloma or relapsed/refractory B-cell lymphoma. The study enrolls 28 patients and focuses on finding the right dose and monitoring for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab, bendamustine, and melphalan (chemotherapy and immunotherapy drugs)
What this could lead to: If this works, it could offer a safer transplant option for older patients with lymphoma or myeloma, with fewer side effects than standard treatments.
What could go wrong: This is a very early phase I trial with only 28 participants, so it is not yet clear if the treatment is effective. The main goal is safety, and there is a risk of serious side effects from the chemotherapy and transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.